These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10980998)

  • 1. Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.
    Kwo PY
    Curr Gastroenterol Rep; 2000 Feb; 2(1):11-7. PubMed ID: 10980998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of interferon therapy nonresponders.
    Shiffman ML
    Clin Liver Dis; 2001 Nov; 5(4):1025-43. PubMed ID: 11685793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
    Shiffman ML
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S13-6. PubMed ID: 15468612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
    Jacobson IM; Gonzalez SA; Ahmed F; Lebovics E; Min AD; Bodenheimer HC; Esposito SP; Brown RS; Bräu N; Klion FM; Tobias H; Bini EJ; Brodsky N; Cerulli MA; Aytaman A; Gardner PW; Geders JM; Spivack JE; Rahmin MG; Berman DH; Ehrlich J; Russo MW; Chait M; Rovner D; Edlin BR
    Am J Gastroenterol; 2005 Nov; 100(11):2453-62. PubMed ID: 16279900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
    Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
    Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C in nonresponders to previous therapy.
    Dantzler TE; Lawitz EJ
    Curr Gastroenterol Rep; 2003 Feb; 5(1):78-85. PubMed ID: 12530952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
    McHutchison JG; Poynard T
    Semin Liver Dis; 1999; 19 Suppl 1():57-65. PubMed ID: 10349693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
    Brouwer JT; Hansen BE; Niesters HG; Schalm SW
    J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?
    Turbide C; Soulellis C; Deschênes M; Hilzenrat N
    Can J Gastroenterol; 2008 Feb; 22(2):149-52. PubMed ID: 18299740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
    BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group.
    Heathcote EJ; James S; Mullen KD; Hauser SC; Rosenblate H; Albert DG
    Hepatology; 1999 Aug; 30(2):562-6. PubMed ID: 10421669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
    Nyberg L; Albrecht J; Glue P; Gianelli G; Zambas D; Elliot M; Conrad A; McHutchison J
    J Clin Gastroenterol; 1999 Jun; 28(4):313-6. PubMed ID: 10372927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
    Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
    Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New trend in treatment in patients with chronic hepatitis C].
    Werling K; Tulassay Z
    Orv Hetil; 2006 Apr; 147(14):637-41. PubMed ID: 16711370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.